Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pathway Modulation
100%
Epidermal Growth Factor
100%
ZD1839
77%
Ductal Carcinoma in Situ
44%
Breast Cancer Cells
33%
ER+ Breast Cancer
33%
Cell Proliferation
22%
Breast Cancer
22%
High-risk Women
22%
ER-negative
22%
Human Epidermal Growth Factor Receptor 2 (HER2)
11%
Tumor Development
11%
Breast Tumor
11%
Chronic Treatment
11%
Cell Death
11%
Contralateral Breast Cancer
11%
Breast Treatment
11%
Chemoprevention Trial
11%
Oral Drugs
11%
Tyrosine Kinase Activity
11%
Antiestrogen
11%
Overexpressing
11%
Mammary Tumor
11%
Mass Spectrometry Analysis
11%
Chemoprevention
11%
Apoptosis
11%
Cell-to-cell
11%
Malignancy
11%
Tyrosine Kinase Inhibitor
11%
Biological Markers
11%
Iressa
11%
Trial Testing
11%
Medicine and Dentistry
Receptor
100%
Intraductal Carcinoma
100%
Epidermal Growth Factor
100%
Gefitinib
88%
Breast Cancer
66%
Cancer Cell
33%
Tamoxifen
22%
Cell Proliferation
22%
Breast Tumor
22%
Proto Oncogene
11%
Biological Marker
11%
Antiestrogen
11%
Cell Death
11%
Diseases
11%
In Vitro
11%
Protein Tyrosine Kinase
11%
Programmed Cell Death
11%
Chemoprophylaxis
11%
Chemoprevention of Breast Cancer
11%
Cancer
11%
Tyrosine-Kinase Inhibitor
11%
Contralateral
11%
Oral
11%
Pharmacology, Toxicology and Pharmaceutical Science
Intraductal Carcinoma
100%
Receptor
100%
Epidermal Growth Factor
100%
Gefitinib
88%
Breast Cancer
77%
Breast Tumor
22%
Tamoxifen
22%
Protein Tyrosine Kinase Inhibitor
11%
Diseases
11%
Biological Marker
11%
Protein Tyrosine Kinase
11%
Antiestrogen
11%